Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
IPO Year:
Exchange: NYSE
Website: freseniusmedicalcare.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | Underperform → Neutral | BofA Securities | |
| 11/6/2024 | $25.60 | Buy | Berenberg |
| 1/8/2024 | Equal-Weight → Underweight | Morgan Stanley | |
| 11/24/2023 | Reduce → Hold | HSBC Securities | |
| 11/17/2023 | Hold → Buy | Societe Generale | |
| 8/14/2023 | Buy → Neutral | UBS | |
| 8/1/2023 | Neutral | Citigroup | |
| 7/12/2023 | Buy | Goldman | |
| 3/7/2023 | Mkt Perform | Bernstein | |
| 1/3/2023 | $14.00 → $11.70 | Buy → Underperform | Jefferies |
Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch
In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholdersFresenius Medical Care delivered 18% operating income growth on an outlook base in 2024Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, released its 2024 Annual Report including its Sustainability Statement. By "Building the Momentum", the Annual Report highlights financial, social, and ecol
Organic revenue growth1 of 4% driven by Care Enablement and Care DeliveryUnderlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full yearAccumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 millionWith 18% operating income2 growth top end of the 2024 outlook range reachedReported operating income grew by 2%, reported net income3 by +8%Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21%High teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% marginBAD HOMBURG, Germany, Feb. 25, 2025 /PRNewswire/ -- "Fresenius Medical
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United StatesBAD HOMBURG, Germany and SECAUCUS, N.J., Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care ((XETRA: FME, NYSE:FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the U.S.
Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and EuropeThe company recorded progress towards its sustainability targetsSustainability is one of the essential drivers for futureBAD HOMBURG, Germany, Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability World Index and with the inclusion in the Dow Jones Sustainability Europe Index for the 15th time. Dow Jones Sustainability Index (DJSI) is one of the world's leading ESG (Environmental, Social, Gove
BAD HOMBURG, Germany, Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, will return to the top tier of the German Stock Index, the DAX 40, as of December 27, 2024. The index represents the performance of the 40 largest publicly traded companies listed on the Frankfurt Stock Exchange and accounts for around 80 percent of the market capitalization of listed stock corporations in Germany. Fresenius Medical Care will return to the top tier of the German Stock Index, the DAX 40, as of De
Strategic Relationship: Agreement expands access to ECMO solutions for hospitals, health systems and patients in the U.S. nationwide.Wide Reach: 4,350+ Premier member hospitals and health systems in the U.S. can leverage pre-negotiated terms and pricing on the Novalung System for ECMO.Commitment to Quality Care: Reinforces company's commitment to supporting healthcare providers in their efforts to deliver high-quality critical care treatments and solutions.BAD HOMBURG, Germany, Nov. 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced its heart and lung group has been awarded a nation
Organic revenue growth of +2% supported by Care Enablement and Care DeliveryUnderlying U.S. dialysis treatment volume growth turns positiveExceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3Both segments further increased operating income1 and operating income margin1Net financial leverage ratio further improved to 2.8xFY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The C
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments.Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.Nearly 75 abstracts presented across a broad range of cutting-edge research, covering topics from the global impact of dialysis to advancements in kidney care technology, sustainability, and health equity.BAD HOMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world'
Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapyThis growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapyThe newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experienceWALTHAM, Mass., Sept. 4, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage
BofA Securities upgraded Fresenius Medical from Underperform to Neutral
Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60
Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight
HSBC Securities upgraded Fresenius Medical from Reduce to Hold
Societe Generale upgraded Fresenius Medical from Hold to Buy
UBS downgraded Fresenius Medical from Buy to Neutral
Citigroup resumed coverage of Fresenius Medical with a rating of Neutral
Goldman initiated coverage of Fresenius Medical with a rating of Buy
Bernstein initiated coverage of Fresenius Medical with a rating of Mkt Perform
Jefferies downgraded Fresenius Medical from Buy to Underperform and set a new price target of $11.70 from $14.00 previously
SC 13G - Fresenius Medical Care AG (0001333141) (Subject)
SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)
SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)
SC 13D/A - Fresenius Medical Care AG & Co. KGaA (0001333141) (Subject)
SC 13G - Fresenius Medical Care AG & Co. KGaA (0001333141) (Subject)
Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.
BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany. Fresenius Medical Care succ
Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a
WALTHAM, Mass., April 5, 2022 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced today the appointment of noted clinical researcher and nephrologist Nwamaka (Amaka) Eneanya, MD as Head of Strategy and Operations for the company's Global Medical Office. Dr. Eneanya was previously an attending nephrologist and Assistant Professor of Medicine and Epidemiology at the University of Pennsylvania, where she served as Director of Health Equity, Anti-Racism, and Community Engagement in the Nephrol
Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch
In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholdersFresenius Medical Care delivered 18% operating income growth on an outlook base in 2024Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, released its 2024 Annual Report including its Sustainability Statement. By "Building the Momentum", the Annual Report highlights financial, social, and ecol
Organic revenue growth1 of 4% driven by Care Enablement and Care DeliveryUnderlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full yearAccumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 millionWith 18% operating income2 growth top end of the 2024 outlook range reachedReported operating income grew by 2%, reported net income3 by +8%Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21%High teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% marginBAD HOMBURG, Germany, Feb. 25, 2025 /PRNewswire/ -- "Fresenius Medical
Organic revenue growth of +2% supported by Care Enablement and Care DeliveryUnderlying U.S. dialysis treatment volume growth turns positiveExceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3Both segments further increased operating income1 and operating income margin1Net financial leverage ratio further improved to 2.8xFY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The C
Organic revenue growth of +2.3% supported by both segments Care Delivery and Care EnablementOperating income1 and operating income margin1 increase driven by Care EnablementAdditional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target rangeFurther divestitures closed as execution of portfolio optimization program continuesNet financial debt and net leverage ratio further improvedFY 2024 outlook confirmedBAD HOMBURG, Germany, July 30, 2024 /PRNewswire/ -- "In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proo
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous yearNew compensation system for Management Board approvedAmbitious growth targets for 2024 confirmedBAD HOMBURG, Germany, May 16, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.
Solid revenue1 growth of 4% driven by both segments Care Delivery and Care EnablementOperating income1 margin improved in both segments Care Enablement delivered strong sequential margin improvement with significant progress towards the 2025 target margin bandExecution of transformation continues at pace, contributing additional FME25 savings of EUR 52 millionPortfolio optimization program progresses in Care Delivery with signed or closed divestments in all our Latin American markets, and closed divestments in Turkiye and of Cura Day Hospitals Group in AustraliaFY 2024 outlook confirmedBAD HOMBURG, Germany, May 7, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical
Revenue growth of 5% in 2023 driven by favorable business developmentOperating income1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contributions from the Tricare settlementSuccessful execution on turnaround plan resulting in significant labor productivity improvements in Care Delivery and positive pricing in Care EnablementSeveral key divestments announced as part of the ongoing Portfolio Optimization ProgramStrong cash flow performance and net financial leverage ratio reducedDividend of €1.19 per share proposedFor 2024 continued revenue growth and accelerated operating income growth projectedBAD HOMBURG, Germany, Feb. 20, 2024 /P
Organic growth accelerated in the second quarter in Care Enablement and Care Delivery including sequentially stable treatment volumes in the U.S.Execution on turnaround plan translates into visible productivity improvements in Care Delivery achieving a Q2 margin at the lower end of the 2025 target margin bandSavings resulting from FME25 transformation program fully on trackSuccessful execution on portfolio optimization strategyLegal form conversion to a German Stock Corporation approved by shareholdersFY 2023 operating income guidance range narrowedWALTHAM, Mass., Aug. 2, 2023 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The second quarter makes evide
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
SCHEDULE 13D/A - Fresenius Medical Care AG (0001333141) (Subject)
SCHEDULE 13D/A - Fresenius Medical Care AG (0001333141) (Subject)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
IRANNOTICE - Fresenius Medical Care AG (0001333141) (Filer)